| Literature DB >> 26319115 |
Abstract
Botanicals are ingredients that can be marketed as foods, drugs, cosmetics, and medical devices in the United States. When a botanical is intended to diagnose, treat, prevent, mitigate, or cure a disease, it is considered to be a "drug". This article reviews the US regulatory requirements for botanicals as "new" drugs. An overview of the regulatory principles used to determine product category and the basic elements of an Investigational New Drug application and New Drug Application with the US Food and Drug Administration are presented. This article is part of a Special Issue entitled "Botanicals for Epilepsy".Entities:
Keywords: Botanical; Drug development; Food and Drug Administration; IND; Investigational New Drug; NDA; New Drug Application; New drug approval; Regulation
Mesh:
Substances:
Year: 2015 PMID: 26319115 DOI: 10.1016/j.yebeh.2015.07.028
Source DB: PubMed Journal: Epilepsy Behav ISSN: 1525-5050 Impact factor: 2.937